

FOR AUSTRALIAN HEALTHCARE PROFESSIONALS

MEETING INVITATION

GSK invites you to an educational event

EVOLVING RESPIRATORY MANAGEMENT



TIME

AGENDA

SPEAKERS



To register directly with your representative, please contact:



To register via QR code, please scan:





COPD & ASTHMA LEARNING OBJECTIVES

Explore the burden of COPD and
ASTHMA in Australia

Focus on the unmet need for patients
with COPD and ASTHMA

Understand the role of TRELEGY
Ellipta, a single inhaler triple therapy in
the management of appropriate COPD
and ASTHMA patients¹

RSV LEARNING OBJECTIVES

Discuss the burden of RSV disease in
older adults

Introduce AREXVY: the only adjuvanted
RSV vaccine for older adults¹

Describe the efficacy and safety of
AREXVY

Develop strategies to implement
AREXVY into your practice

TRELEGY Ellipta

PBS Information: **Severe asthma** (200/62.5/25 mcg presentation only); **Chronic obstructive pulmonary disease** (100/62.5/25 mcg presentation only): Authority Required (streamlined). Criteria apply. Refer to PBS for full information.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product Information can be accessed at www.gsk.com.au/trelegy

Indications¹: COPD: Maintenance treatment of adults with moderate to severe COPD who require LAMA+LABA+ICS (100/62.5/25 mcg presentation only). Not indicated for initiation in COPD. Asthma: Maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA. **Contraindications**¹: Severe milk-protein allergy or hypersensitivity to any of the ingredients. **Pregnancy**¹: Category B3. **Adverse Effects**¹: Nasopharyngitis, headache, cough, oropharyngeal pain, pneumonia, upper respiratory tract infection, viral respiratory tract infection, influenza, pharyngitis, dysphonia, rhinitis, arthralgia, back pain, constipation, sinusitis, bronchitis, urinary tract infection, candidiasis of mouth and throat. **Dosage**¹: COPD: TRELEGY 100/62.5/25 mcg: One inhalation once daily. After inhalation, rinse mouth with water without swallowing. Asthma: TRELEGY 100/62.5/25 mcg or TRELEGY 200/62.5/25 mcg: One inhalation once daily. After inhalation, rinse mouth with water without swallowing.

AREXVY

PBS Information: AREXVY is not listed on the PBS or the National Immunisation Program (NIP).

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product Information can be accessed at www.gsk.com.au/arexvy

Indication²: AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV). Vaccines may not protect all recipients. **Dosing and administration**²: AREXVY is administered as a single, reconstituted dose of 0.5mL by intramuscular injection. The need for revaccination has not been established. **Safety**²: Very common adverse events (≥10%) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events (≥1%) are injection site erythema, injection site swelling, fever, chills and rhinorrhoea (not a complete list; see full PI).

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Abbreviations: COPD, chronic obstructive pulmonary disease; RSV, respiratory syncytial virus

References: 1. TRELEGY Product Information 2. AREXVY Product Information

This educational activity was initiated, developed and organised by GSK. This is an educational event for your professional development. Therefore, accompanied persons such as family members or friends are not invited to attend.

We GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding our activities and products or developments in pharmaceutical treatments which may be of interest to you. We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all our services. Our privacy policy can be found at <https://privacy.gsk.com/en-au/privacy-notice/general/> and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd, PO Box 18095, Melbourne, Victoria, 8003

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481, Melbourne, VIC PM-AU-RSA-LBND-240003 Date of approval: February 2024.

TRELEGY ELLIPTA
fluticasone furoate/umeclidinium/vilanterol

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS
VACCINE RECOMBINANT, ADJUVANTED)



SCAN QR CODE
to see full
TRELEGY Ellipta
Product Information



SCAN QR CODE
to see full AREXVY
Product Information